405 filings
Page 9 of 21
6-K
g6csj
16 Feb 18
Current report (foreign)
12:00am
SC 13G/A
uh6sd7
14 Feb 18
Intellipharmaceutics International Inc.
12:00am
6-K
0em8sa jdhi2d02
14 Feb 18
Intellipharmaceutics Sets Earnings Release Date for Year End 2017 Results
12:00am
6-K
fx4qunzq6i c0
9 Feb 18
Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program
12:00am
6-K
81bfi7t0mffd2n103f
24 Jan 18
Intellipharmaceutics Provides Operational Update
12:00am
6-K
hpnwf
5 Dec 17
Intellipharmaceutics Announces Receipt of Nasdaq Notice
12:00am
SC 13G
jvjvs92e5a4wdv
4 Dec 17
Intellipharmaceutics International Inc.
12:00am
6-K
1wk4xd7f h821ew
30 Nov 17
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
12:00am
SC 13G
vzdrv
20 Oct 17
Intellipharmaceutics International Inc.
12:00am
D
ctdzewr 86
18 Oct 17
$2.52M in options / securities to be acquired, sold $2.52M, 6 investors
12:00am
6-K
v2wui
16 Oct 17
Intellipharmaceutics Announces Closing of US$4 Million Financing
12:00am
424B5
xcnnnez yew
13 Oct 17
Prospectus supplement for primary offering
12:00am
6-K
dwwarj
12 Oct 17
Primary Document
12:00am
6-K
blye7x 4d4q0kk08
11 Oct 17
Intellipharmaceutics Announces US$4 Million Registered Direct Offering
12:00am
6-K
7nqtvqtxkhfem
10 Oct 17
Primary Document
12:00am
6-K
gyn jdstqtczxr9pq
25 Sep 17
Intellipharmaceutics Receives Complete Response Letter from the FDA for RexistaTM NDA
12:00am
6-K
vm75i4 l9
20 Sep 17
Intellipharmaceutics Announces Receipt of Nasdaq Notice
12:00am
6-K
gfww4xgcrfzms5zz
5 Sep 17
Intellipharmaceutics Provides Operational Update
12:00am
6-K
gdqyln3gl kgu
1 Sep 17
Intellipharmaceutics Appoints New Chief Financial Officer
12:00am
6-K
x6ww2wz58jv9mwzxlqi
8 Aug 17
Intellipharmaceutics Announces Resignation of Chief Financial Officer
12:00am